News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Sorin Group S.p.A. Announces Third Quarter 2008 Results. EBITDA and EBIT Margins above Market Guidance and Strongly Improving versus Last Year. Significant Reduction in Net Debt over the Last Twelve Months.
November 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MILAN, Italy--(BUSINESS WIRE)--Sorin Group (MIL:SRN) Revenues were €175.6 million, stable°(**) compared to Q3 2007;
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Layoff Tracker
Ferring To Cut 500 Employees as Part of Business Model Shift
October 10, 2025
·
70 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover
October 10, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
GoodRx Wants In on Direct-to-Consumer TrumpRx Platform
October 10, 2025
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novo Strikes up to $5.2B Deal for Akero in Red-Hot MASH Space
October 9, 2025
·
2 min read
·
Annalee Armstrong
